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study
Yasuhiro Shimojima, Wataru Ishii, Masayuki Matsuda*, Ko-ichi Tazawa and Shu-ichi IkedaAbstract
Background: To investigate whether or not coadministration of tacrolimus (TAC) with prednisolone (PSL) can
produce a beneficial effect in the treatment of polymyositis/ dermatomyositis (PM/DM).
Methods: We reviewed medical records of 32 PM/DM patients who had been admitted to our hospital, and
abstracted those who had received TAC in addition to oral PSL for treatment. The clinical usefulness of TAC in
PM/DM was objectively evaluated focusing upon the manual muscle strength test (MMT) score, serum creatine
kinase (CK) and tapering of PSL.
Results: Nine patients with PM and 6 with DM were enrolled in this study. TAC was added because of difficulty in
reduction of PSL in 12 patients and recurrence with corticosteroid-induced complications in the remaining 3. Both
PM and DM patients showed significant increases in the MMT score and significant decreases in serum CK 1 to
3 months after starting TAC compared with before. Skin symptoms in a clinically amyopathic DM patient also
improved 1 month after starting TAC. The daily dosage of PSL could be significantly reduced in both PM and DM
after starting TAC compared with before. No serious adverse events ascribable to TAC occurred in any patients.
Conclusion: Additional use of TAC with PSL may safely promote improvement of PM/DM and also accelerate
tapering of the latter.
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Polymyositis (PM) and dermatomyositis (DM) are in-
flammatory systemic disorders characterized clinically by
involvement of skeletal muscles, such as limb weakness
and myalgia, with or without skin symptoms [1]. As an
autoimmune mechanism is considered to be central to
the pathogenesis of these diseases, corticosteroid has
usually been employed as the first-line treatment. In
some patients, however, clinical symptoms are resistant
to corticosteroid, or this drug is not usable at a high
dose for a long period because of complications, includ-
ing infection and progressive osteoporosis, particularly* Correspondence: matsuma@shinshu-u.ac.jp
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distribution, and reproduction in any mediumin elderly people. In such cases coadministration of im-
munosuppressive agents is the next candidate therapy.
Tacrolimus (TAC) is a relatively new immunosuppres-
sant, which acts as a calcineurin inhibitor, and selectively
and reversibly suppresses T lymphocytes secreting cyto-
kines, such as interleukin-2 [2]. Our previous report has
demonstrated that TAC can promote recovery of refrac-
tory cases of myasthenia gravis, which is one of the organ-
specific autoimmune disorders, in cooperation with oral
prednisolone (PSL) [3]. As activated T lymphocytes play
an important role in the pathogenesis of PM/DM [4-7],
coadministration of TAC with oral PSL may be able to
promote early recovery from these disorders, and reduce
corticosteroid-induced adverse events [4,8-11]. In the
present study we retrospectively investigated the clinical
course of PM/DM patients who had received TAC intral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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verse effects of the former. We postulate that additional
use of TAC may be beneficial for PM/DM patients with




We reviewed medical records of 32 Japanese patients
(11 men and 21 women; age range, 22 to 81 years; mean,
54.5 ± 9.1 years) who had been admitted to Shinshu
University Hospital for treatment of PM/DM between
January 2006 and August 2010. Three of the authors
(YS, MM and KT) abstracted the data for serum creat-
ine kinase (CK), visible rash, and histopathology of the
muscle and/or skin before treatment, and confirmed
that all of the patients suffered from PM/DM according
to the criteria proposed by Bohan and Peter [1]. Demo-
graphic parameters, including age and gender, and med-
ical history of treatment for PM/DM were abstracted
simultaneously. All of the patients who had received TAC
in addition to PSL were enrolled in this study. We
obtained further clinical information from their medical
records, such as serum CK, muscle strength, skin symp-
toms and the daily dosage of TAC and PSL during treat-
ment, onset age, disease duration, autoantibodies and the
history of associated diseases, particularly malignancy and
interstitial pneumonia. The Committee for Medical Ethics
of Shinshu University School of Medicine approved this
study (No. 1986).
Protocol for TAC administration
To check renal and liver function prior to commence-
ment of TAC, each patient receives routine laboratory
examinations, including hematology, blood chemistry,
creatinine clearance and urinalysis. We administer oral
TAC (PrografW, Asteras, Osaka, Japan) to the patients
with their informed consent unless laboratory data show
1.5 mg/dL or higher levels of serum creatinine or the
presence of serious associated diseases, such as severe
diabetes mellitus. The dosing protocol for TAC in our
hospital is as follows: the daily dosage is started in
principle at 2 mg in a single dose, and is increased to
3 mg after 2 weeks as long as there have been no adverse
events ascribable to this drug, such as eruptions or a
rapid increase in serum creatinine. We check the trough
concentration of TAC at least every other month. When
the trough concentration either exceeds 15 ng/mL or is
between 10 and 15 ng/mL on two successive occasions,
the daily dosage is reduced 1 mg at a time. On starting
TAC oral PSL is continued in principle at the same
dosage as before. To detect development of hyperten-
sion and abnormalities in laboratory data such as renal
dysfunction and hyperglycemia as early as possible,hematology and blood chemistry as well as blood pres-
sure are examined at least every week during admission
and every month at the outpatient clinic. If the serum
creatinine levels double despite dose adjustment, TAC
is discontinued. The dosage of oral PSL is reduced after
starting TAC at varying doses and speeds as necessary.
Clinical and laboratory assessment of therapeutic
outcomes
We used the following information as objective clinical
markers for therapeutic outcomes of TAC: the results of
the manual muscle strength test (MMT), which had
been performed by 4 of the authors (YS, WI, MM and
KT) according to the standard method [12], values of
serum CK and the daily dosage of oral PSL. On the basis
of the results of MMT, muscle strength in both sides of
the deltoid, biceps brachii, triceps brachii, iliopsoas,
quadriceps femoris and hamstrings was semiquantitavely
graded before and during treatment using the rating
scale from 0 to 5 (0: no contraction, 1: visible contrac-
tion but immovable, 2: movable without gravity but im-
movable against it, 3: movable against gravity, 4: slight
decrease, 5: normal), and the sum was defined as the
MMT score with a healthy state thus being 60. Increases
in the MMT score and/or decreases in serum CK indi-
cated clinical improvement of PM/DM. In DM patients
with visible rash but no muscle involvement therapeutic
effects of TAC were evaluated with macroscopic findings
of skin symptoms alone. We abstracted clinical informa-
tion on adverse events ascribable to TAC focusing upon
infection, renal and liver dysfunction and hyperglycemia.
Statistics
Wilcoxon’s signed rank test was used in order to deter-
mine statistical differences in the MMT score, serum
levels of CK and the dosage of oral PSL between before
and after adding TAC. The results were expressed as
mean ± standard deviation, and a p-value less than 0.05
was regarded as statistically significant. Commercially
available statistics software was used for data analysis
(StatView for Macintosh, Abacus Concepts, Berkeley,
CA, USA).
Results
Nine patients with PM (2 men and 7 women; mean age
48.0 ± 15.2 years, range 17 to 63) and 6 with DM (1 man
and 5 women; mean age 50.7 ± 18.8 years, range 24 to
72) received TAC for treatment, and met the criteria for
our review. The rest were treated with either PSL alone
(n = 8) or PSL and cyclosporine A (CyA) (n = 9). Clinical
profiles of the 15 patients enrolled in this study are sum-
marized in Table 1. One of the DM patients (patient 15)
was compatible with clinically amyopathic DM (CADM)
with regard to showing typical skin symptoms, including




























1 F PM 17 - - DRP 3 - 50 838 35 -
2 F PM 37 + - DRP 4 - 53 775 30 -
3 F PM 46 - - DRP 5 - 60 666 15 -
4 M PM 55 - - DRP 5 - 60 482 15 -
6 F PM 61 - - DRP 1 - 47 2241 45 -
7 F PM 63 - - DRP 1 - 47 965 30 -
8 F PM 37 - - Recurrence 180 Osteoporosis,
multiple rib
fracture
40 1809 2.5 -
9 M PM 57 - - Recurrence 32 Glaucoma 60 810 4 -
10 F DM 31 - + DRP 1 - 47 1665 50 -
11 M DM 58 - - DRP 1 - 45 612 60 -
12 F DM 59 - - DRP 1 - 35 3699 30 -
13 F DM 60 - - DRP 1 - 35 3699 50 -
14 F DM 72 - - Recurrence 8 Osteoporosis 35 864 20 -
15 F CADM 24 - - DRP 1 - 60 74 25 -
CADM: clinically amyopathic dermatomyositis, CK: creatine kinase, DM: dermatomyositis, DRP: difficulty in reduction of prednisolone, MMT: manual muscle
strength test, PSL: prednisolone, TAC: tacrolimus.
Shimojima et al. BMC Musculoskeletal Disorders 2012, 13:228 Page 3 of 6
http://www.biomedcentral.com/1471-2474/13/228heliotrope rash, Gottron’s sign and ulceration, with no
or little muscle involvement [13]. No patients had either
malignancy or visceral organ involvement, particularly
acute interstitial pneumonia, on intensive systemic sur-
vey. The anti-nuclear and anti-Jo-1 antibodies were
detected in 1 patient each with PM and DM, respect-
ively. The reason for adding TAC was difficulty in reduc-
tion of oral PSL in 12 patients and recurrence of either
muscle symptoms or CK elevation in 3. As the dosage of
PSL could not be increased in the latter because of
corticosteroid-induced complications, such as progres-
sive osteoporosis and glaucoma, TAC was added for
treatment. On starting TAC, disease duration, the MMT
score, serum CK and the daily dosage of oral PSL were
16.6 ± 45.9 months, 49.1 ± 8.6, 1089.7 ± 925.8 IU/L and
28.8 ± 17.0 mg, respectively. No abnormalities were
found in laboratory data except for increases in acute
phase reactants and muscle-related enzymes, such as CK
and lactate dehydrogenase. All of the patients received
TAC according to our protocol except for 2 (patients 6
and 9), in whom this drug was started at 1.5 mg/day and
maintained at 2 mg/day at their request. The trough con-
centration of TAC remained between 2.5 and 6.0 ng/mL in
all of the patients. We had available data for the MMT
score, serum CK, the daily dosage of oral PSL and ad-
verse events ascribable to TAC in all of the 15 patients
enrolled in this study.Temporal profiles of the MMT score are shown in
Figure 1. The MMT score was significantly higher in
both PM and DM 3, 6 and 12 months after adding TAC
compared with before (p < 0.05). The DM patients
showed a significant increase in the MMT score also
1 month after adding TAC in comparison with before
(p < 0.05). Heliotrope rash and other skin symptoms in
a CADM patient persisted even with oral PSL alone,
but quickly improved 1 month after adding TAC. Tem-
poral profiles of serum CK are shown in Figure 2. In
PM serum CK obviously decreased 1 month after add-
ing TAC in all of the patients, and of these 6 showed
approximate normalization in the following 2 months.
No obvious reincrease in serum CK was seen in any
patients. Serum CK was significantly lower 1 month
after adding TAC comapred with before (p < 0.05), and
a similar significant difference was seen also 3, 6 and
12 months after commencement of this drug (p < 0.01).
In DM serum CK obviously decreased after adding
TAC in all the patients, and was normalized in
3 months. No reincrease was seen in any patients.
Serum CK was significantly lower 1, 3, 6 and 12 months
after adding TAC compared with before (p < 0.05).
Temporal profiles of oral PSL are shown in Figure 3.
All of the patients showed successful reduction of oral
PSL to 20 mg daily or less within 12 months after add-



































Figure 1 Temporal profiles of the MMT score from diagnosis in patients with PM (A) and those with DM (B), showing significant
increases 3, 6 and 12 months after adding TAC compared with before (*p < 0.05). A similar significant change is seen also 1 month after
adding TAC in the DM patients. Time point of adding TAC is indicated as 0. #Data of patients 8 and 9 are shown from 6 months before
adding TAC.
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ing TAC compared with before (p < 0.05). The DM
patients showed a significant decrease in the daily dos-
age of PSL also 3 months after adding TAC in compari-
son with before (p < 0.05). We could not find any
clinical information or laboratory data suggestive of
serious adverse events ascribable to TAC in the medical
records of any patients.
Discussion
The present study showed 2 possible advantages of using
TAC in the treatment of PM/DM. One is acceleration of
recovery. Both PM and DM patients showed significant
increases in the MMT score and significant decreases in





















Figure 2 Temporal profiles of serum CK from diagnosis in patients w
1, 3, 6 and 12 months after adding TAC compared with before (*p < 0
#Data of patients 8 and 9 are shown from 6 months before adding TAC.with before. In a patient with CADM obvious improve-
ment of skin symptoms was seen 1 month after starting
TAC. Considering that some of the clinical manifestations
and laboratory data suggestive of active disease, such as
muscle weakness, skin symptoms and elevated levels of
serum CK, worsened or remained unimproved in all of
the patients even with oral PSL alone at the same dosage
for at least 1 month, commencement of TAC may have
produced additional therapeutic effects on PM/DM. Few
case reports have so far described such clinical efficacy of
TAC in PM/DM [14-16], and the present study first
demonstrated it in a series of patients. The MMT score in
some PM patients fluctuated even while they were being
treated with PSL and TAC, and full recovery of muscle
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Figure 3 Temporal profiles of oral PSL from diagnosis in patients with PM (A) and those with DM (B), showing significant decreases 6
and 12 months after starting TAC compared with before (*p < 0.05). A similar significant change is seen also 3 months after adding TAC in
the DM patients. Time point of adding TAC is indicated as 0. #Data of patients 8 and 9 are shown from 6 months before adding TAC.
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patients with DM than for those with PM.
The other possible advantage of using TAC in the
treatment of PM/DM is early and rapid reduction of cor-
ticosteroid. As oral PSL, which is often used as a kind of
corticosteroid, frequently causes adverse events such as
osteoporosis and compression fracture of the spine,
long-term use of it should be avoided if possible, par-
ticularly in postmenopausal women. Coadministration of
TAC can probably enhance immunosuppressive poten-
tial and may be able to shorten the period of high-dose
corticosteroid therapy. In the present study both PM
and DM patients showed significant decreases in the
daily dosage of oral PSL 3 to 6 months after starting
TAC compared with before. These results suggest that
additional use of TAC may be able to actually reduce the
daily dosage of PSL without worsening of clinical symp-
toms and laboratory data. PSL could be maintained at a
low dose after adding TAC upon recurrence in 2 PM
and 1 DM patients with serious complications ascribable
to corticosteroid, such as progressive osteoporosis.
These PM/DM patients also showed favorable thera-
peutic outcomes. Coadministration of TAC in PM/DM
may be able to contribute not only to dose reduction
of PSL but also to improvement of symptoms and
normalization of serum CK even under low-dose PSL,
particularly in cases with corticosteroid-induced com-
plications in the long clinical course. The present study
is, however, a retrospective uncontrolled one in a single
center. To more clearly show the therapeutic effects of
TAC in PM/DM, a randomized controlled multi-center
study in a larger set of patients is necessary.
TAC sometimes causes various adverse events, such as
renal dysfunction and diabetes mellitus, which depend
on its blood concentration [17,18]. We, therefore, usu-
ally adjust the daily dosage of TAC based on the troughconcentration in order to avoid adverse effects due to
this drug. In the present study the daily dosage of TAC
was 1.5 mg to 3.0 mg, and no serious adverse events oc-
curred in any patients under a trough concentration of
at most 6 ng/mL. According to recent reports, adverse
effects of TAC can be adequately avoided by keeping the
trough value less than 10 ng/mL [19,20]. TAC might be
safely usable at or below 3 mg/day, which is officially
approved as a standard dose, in PM/DM without fre-
quent monitoring of the trough concentration as long as
renal function is almost normal. We can expect potent
therapeutic effects from TAC by giving the whole dose
at one time as done in this study because the trough
concentration is more definitively increased than when
administered in a divided dose [21-23]. CyA is also an
immunosuppressive agent which acts as a calcineurin in-
hibitor [2], but frequent adjustment of the dose accord-
ing to the trough concentration is sometimes necessary
in order to increase therapeutic effects and prevent ad-
verse events. TAC might be superior to CyA with regard
to the lack of need for frequent monitoring of the trough
concentration, particularly when using these drugs in
the outpatient clinic.Conclusions
Coadministration of TAC with PSL is probably the well-
tolerated first-line therapy next to the latter alone in
PM/DM with regard to both therapeutic effects and safety.
Additional use of TAC may also lead to rapid reduction of
PSL, which is particularly important for PM/DM patients
with various complications ascribable to corticosteroid in
the long clinical course.Competing interests
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